Renal Cancer Trials

From DolceraWiki
Jump to: navigation, search

To go back to the main page, click here


S.No Drug Name Biological Name Developer Current Development Phase Additional Information Start Date Completion Date Source
11 Sunitinib, Cyclophosphamide IMA901 plus GM-CSF Immatics Biotechnologies GmbH III The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy with sunitinib. Secondary objectives include a subgroup analysis of overall survival in patients defined by a certain biomarker signature, the investigation of progression-free survival, best tumor response, safety, and immunological parameters 2010 2011 Source
12 - PSMA/PRAME MannKind Corporation I Completed
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.
2007 2009 Source
13 - EphA2 Vaccine/
MEDI-543
MedImmune Preclinical - - - -
14 - V934/V935 Merck I Completed.
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
2008 2011 Source
15 - MGN1601 Mologen AG I/II This is a Phase 1/2, proof-of-principle clinical study to assess safety and efficacy of a intradermally administered tumor vaccine (MGN1601). The study will be conducted in patients with advanced renal cell carcinoma. 2010 2019 Source
16 Interferon-alpha TroVax® Oxford BioMedica II Patients with metastatic renal cell cancer will be enrolled to receive either Trovax® alone or Trovax® plus Interferon Alfa. The study will try to determine whether the use of Trovax® will delay tumor progression. 2006 2008 Source
17 - AdhTAP TapImmune Preclinical - - - -




To go back to the main page, click here